ストックスクリーナーアプリを入手
54.80
2.45%
1.31
前日終値:
$53.49
開ける：
$53.58
24時間の取引高:
416.14K
Relative Volume:
0.84
時価総額：
$3.40B
収益：
$112.53M
当期純損益:
$-258.91M
株価収益率:
-12.66
EPS:
-4.33
ネットキャッシュフロー:
$-124.42M
1週間 パフォーマンス:
+5.30%
1か月 パフォーマンス:
+3.40%
6か月 パフォーマンス:
+6.72%
1年 パフォーマンス:
+26.47%
1日の値動き範囲:
$53.02
$55.21
1週間の範囲:
$52.12
$55.21
52週間の値動き範囲:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
名前
Rhythm Pharmaceuticals Inc
セクター
電話
857-264-4280
住所
222 BERKELEY STREET, BOSTON, MA
RYTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
54.80 | 3.40B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2025-01-02 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Guggenheim | Buy |
| 2024-09-18 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-08-08 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-05 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 繰り返されました | Needham | Buy |
| 2022-03-02 | 再開されました | Stifel | Buy |
| 2022-02-17 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 再開されました | Goldman | Neutral |
| 2021-08-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-08-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-08 | 開始されました | Goldman | Sell |
| 2019-07-12 | アップグレード | Stifel | Hold → Buy |
| 2019-07-08 | 開始されました | Canaccord Genuity | Buy |
| 2019-03-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-09-07 | 再開されました | Morgan Stanley | Overweight |
| 2018-06-25 | 繰り返されました | Needham | Buy |
| 2018-06-15 | 繰り返されました | Needham | Buy |
| 2017-10-30 | 開始されました | BofA/Merrill | Buy |
| 2017-10-30 | 開始されました | Needham | Buy |
すべてを表示
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Equities Analysts Offer Predictions for RYTM Q1 Earnings - Defense World
Q2 Earnings Estimate for RYTM Issued By HC Wainwright - Defense World
Swiss National Bank Has $5.05 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given Buy Rating at HC Wainwright - Defense World
Rhythm Pharmaceuticals corporate controller sells shares for $18,655 By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals corporate controller sells shares for $18,655 - Investing.com India
Analyst Expectations For Rhythm Pharmaceuticals's Future - Benzinga
Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? - MSN
(RYTM) Proactive Strategies - Stock Traders Daily
Rhythm Pharma ends RareStone licensing deal in China - MSN
Rhythm Pharma stock down as licensing deal ends (RYTM:NASDAQ) - Seeking Alpha
Victory Capital Management Inc. Reduces Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals regains rights to obesity drug in China By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. - Marketscreener.com
Rhythm Pharmaceuticals regains rights to obesity drug in China - Investing.com India
Rhythm Pharmaceuticals Reacquires Licensing Rights to - GlobeNewswire
Strategic Win: Rhythm Pharmaceuticals Reclaims IMCIVREE Rights in China, Strengthens Global Position - StockTitan
Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Rhythm Pharmaceuticals receives orphan drug status in Japan By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com
Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan - The Manila Times
Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com India
Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire
Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com
How To Trade (RYTM) - Stock Traders Daily
SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Overweight Rating from Morgan Stanley - Defense World
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts - Benzinga
Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential - TipRanks
Stifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $68.27 - Defense World
HC Wainwright Brokers Raise Earnings Estimates for RYTM - Defense World
Citizens JMP maintains Rhythm Pharma Outperform, $81 target By Investing.com - Investing.com South Africa
Citizens JMP maintains Rhythm Pharma Outperform, $81 target - Investing.com India
Rhythm Pharmaceuticals Inc (RYTM) 財務データ
収益
当期純利益
現金流量
EPS
Rhythm Pharmaceuticals Inc (RYTM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mazabraud Yann | EVP, Head of International |
Mar 14 '25 |
Option Exercise |
22.28 |
75,000 |
1,671,000 |
115,370 |
| Mazabraud Yann | EVP, Head of International |
Mar 14 '25 |
Sale |
51.48 |
75,000 |
3,861,272 |
40,370 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):